According to the company, Kendrick will enable Sanofi-Aventis to reinforce its leadership in Mexico and further extend the range of its pharmaceutical portfolio. This acquisition is claimed to be important for the growth of the company.
Nicolas Cartier, general manager of Sanofi-Aventis Mexico, said: “The Kendrick acquisition represents an exceptional opportunity to accelerate our growth in the generic market in Mexico. Sanofi-Aventis proves once again its leadership and its commitment to offering quality medicines that satisfy the patient needs with one of the most comprehensive portfolios in the industry.”